


2-Deoxy-D-galactose

| | |
|--------------------|------------------------------------------------------------------------------------------------|
| Cat. No.: | HY-131892 |
| CAS No.: | 1949-89-9 |
| Molecular Formula: | C ₆ H ₁₂ O ₅ |
| Molecular Weight: | 164.16 |
| Target: | Others |
| Pathway: | Others |
| Storage: | 4°C, protect from light * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light) |



SOLVENT & SOLUBILITY

In Vitro

H₂O : 250 mg/mL (1522.90 mM; Need ultrasonic)
Methanol : 125 mg/mL (761.45 mM; Need ultrasonic)

| Preparing Stock Solutions | Solvent | Mass | 1 mg | 5 mg | 10 mg |
|---------------------------|---------------|------|-----------|------------|------------|
| | Concentration | | | | |
| | 1 mM | | 6.0916 mL | 30.4581 mL | 60.9162 mL |
| | 5 mM | | 1.2183 mL | 6.0916 mL | 12.1832 mL |
| | 10 mM | | 0.6092 mL | 3.0458 mL | 6.0916 mL |

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

2-Deoxy-D-galactose is a glucose analog. 2-Deoxy-D-galactose inhibits glycolysis to inhibit tumor growth. 2-Deoxy-D-galactose is a substance interfering with the fucosylation of glycomacromolecules and impairing memory consolidation in various learning tasks. 2-Deoxy-d-galactose hinders glycoprotein fucosylation in vivo^[1].

In Vitro

2-Deoxy-D-galactose (1 mM/L; 5 h) is rapid phosphorylation during the first 30 min and decreases to approximately 20% of this rate during the subsequent hours in ascites hepatoma cells^[4].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

2-Deoxy-D-galactose (380 mg/kg; i.p.; for 6 times) strongly decreases contents of UMP, UDPG, and UDP galactose in rat livers^[1].
2-Deoxy-D-galactose (2-8 μM; intracerebroventricularly injection; once) shows PAR impairment 30 min before the acquisition trial a dose of 4 μM and 15 min delay after do-gal administration^[3].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

| | |
|-----------------|-----------------------------------------------------------------------------------------------|
| Animal Model: | Male adult Wistar rats with passive avoidance response (PAR) acquisition trial ^[3] |
| Dosage: | 2, 4 and 8 μ M |
| Administration: | Intracerebroventricularly injection; 2-8 μ M; once |
| Result: | Exhibited PAR disruption at a dose of 4 μ M. |

REFERENCES

- [1]. Keppler DO, et al. The trapping of uridine phosphates by D-galactosamine, D-glucosamine, and 2-deoxy-D-galactose. A study on the mechanism of galactosamine hepatitis. *Eur J Biochem.* 1970 Dec;17(2):246-53.
- [2]. Krug M, et al. The amnesic substance 2-deoxy-D-galactose suppresses the maintenance of hippocampal LTP. *Brain Res.* 1991 Feb 1;540(1-2):237-42.
- [3]. Lorenzini CG, et al. 2-Deoxy-D-galactose effects on passive avoidance memorization in the rat. *Neurobiol Learn Mem.* 1997 Nov;68(3):317-24.
- [4]. Smith DF, Keppler DO. 2-Deoxy-D-galactose metabolism in ascites hepatoma cells results in phosphate trapping and glycolysis inhibition. *Eur J Biochem.* 1977 Feb 15;73(1):83-92.
-

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA